SEC Tracker
Get the app

STAAR Surgical STAA

Staar Surgical reports Q3 2026 results

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Net sales of $83.4 million
  2. Net income of $5.6 million
  3. Adjusted EBITDA of $14.4 million
  4. Record revenue of $270.5 million for first three quarters

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when STAAR Surgical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release as Exhibit 99.1, which details the company's financial performance.
  2. Item 2.02 of the Form 8-K provides results of operations and financial condition for the quarter ended October 2, 2026.
  3. The company also scheduled a conference call to discuss these results.
  4. The Form 8-K includes a cover page interactive data file as Exhibit 104.
  5. The filing was signed by the company's Chief Financial Officer, Deborah Andrews.

5 of 5 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended July 3, 2026

  • In its 10-Q for the quarter ended July 3, 2026, STAAR Surgical Company reported revenue of $93.5 million.
  • Net income for that period was $8.1 million.
  • The company's revenue increased by 111.0% compared to the same period a year earlier.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.2

On November 4, 2026, STAAR Surgical Company (the "Company") published a press release reporting its financial results for the quarter ended October 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report1 and is incorporated herein by this reference.

Item 7.01 Regulation FD Disclosure.

During a conference call and webcast scheduled to be held at 5:30 p.m.3 3Eastern / 2:30 p.m.3 3Pacific on November 4, 2026, the Company's President and Chief Executive Officer and the Company's Executive Vice President and Chief Financial Officer will discuss the Company's results for the quarter ended October 2, 20263.

The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press release of the Company dated November 4, 2026.

1044

Cover Page Interactive Data File (embedded within the Inline XBRL document).4

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company

November 4, 2026

By:5

/s/ DEBORAH ANDREWS5

Deborah Andrews5

Executive Vice President and Chief Financial Officer5

Similar companies

Companies of similar size in SIC 3851 and related industry codes: the same peer list as the financial tables.

  1. National Vision Holdings EYE public float $1.3B, Jun 28, 2025
  2. Bausch & Lomb BLCO public float $557M, Jun 30, 2025
  3. RxSight RXST public float $504M, Jun 30, 2025
  4. Warby Parker WRBY public float $2.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.